A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer

Inclusion Criteria: * 1.Male or female, ≥ 18 of age; * 2.Histological confirmed advanced colorectal adenocarcinoma，and at least one measurable lesion; * 3.Have failed for ≥ 2 lines of standard chemotherapy(included Fluorouracil, irinotecan and oxaliplatin); * 4.ECOG performance status 0-2; * 5.Life expectancy of more than 3 months; * 6.The main organs function is well, and randomized within 14 days before the relevant inspection indicators to meet the following requirements: 1. blood routine test Hgb ﹥90g/L, ANC﹥1.5×109/L, Platelets ﹥ 100×109/L, 2. biochemical tests Serum Total bilirubin ≤ 1.5 X UNL(upper normal limit), ALT or AST ≤ 2 xUNL, and ﹤ 5 x UNL（Hematogenous metastases）, Creatinine clearance rate≥ 60 ml/min(Cockcroft-Gault formula), 3. Doppler echocardiography assessment：LVEF ≥ 50%; * 7.No serious heart, lung, liver, kidney dysfunction; no jaundice and gastrointestinal obstruction; no acute infection; * 8.Signed informed consent; * 9.Good compliance, and family members agree to receive survival follow-up. Exclusion Criteria: * 1.Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);